G Morgan Jones1,2,3, Brandon Cave1,2, Ryan Cook4. 1. Department of Pharmacy, Methodist University Hospital, Memphis, TN, USA. 2. Department of Clinical Pharmacy, University of Tennessee Health Sciences Center (UTHSC), Memphis, TN, USA. 3. Departments of Neurology and Neurosurgery, UTHSC, Memphis, TN, USA. 4. Department of Pharmacy, Baptist Medical Center, Jacksonville, FL, USA.
Abstract
BACKGROUND AND PURPOSE: Current guidelines suggest that 3-factor prothrombin complex concentrate is a possible alternative to 4-factor products for the emergent reversal of bleeding secondary to warfarin. While multiple observational studies have evaluated various forms of 3-factor prothrombin complex concentrate individually, no study has compared the efficacy of the 2 products. The purpose of this study is to compare the efficacy and safety of Bebulin™ and Profilnine™ for the emergent reversal of warfarin-associated major bleeding. METHODS: We conducted a retrospective cohort study of patients receiving both Bebulin™ and Profilnine™ at an urban, academic medical center with comprehensive stroke center designation and a neurosurgical center of excellence. All patients were treated at a single center that utilized a fixed, weight-based dosing protocol. The primary outcome was the percentage of patients in each group achieving a goal international normalization ratio of 1.4 or less. RESULTS: There was a significant difference in goal international normalization ratio achieved favoring Bebulin™ (85.5% vs 27.3%; P < .001) over Profilnine™. Median dose per kilogram of actual body weight was the same between the groups. When we assessed results by baseline™ international normalization ratio subgroup, more patients in the Bebulin™ group achieved goal when baseline values were 6 or less. No thrombotic events were documented in either group. CONCLUSIONS: We found that patients treated with Bebulin™ experienced significantly higher rates of successful international normalization ratio reversal when compared to those who received Profilnine™. Further research is needed to determine the comparative efficacy between the 2 agents.
BACKGROUND AND PURPOSE: Current guidelines suggest that 3-factor prothrombin complex concentrate is a possible alternative to 4-factor products for the emergent reversal of bleeding secondary to warfarin. While multiple observational studies have evaluated various forms of 3-factor prothrombin complex concentrate individually, no study has compared the efficacy of the 2 products. The purpose of this study is to compare the efficacy and safety of Bebulin™ and Profilnine™ for the emergent reversal of warfarin-associated major bleeding. METHODS: We conducted a retrospective cohort study of patients receiving both Bebulin™ and Profilnine™ at an urban, academic medical center with comprehensive stroke center designation and a neurosurgical center of excellence. All patients were treated at a single center that utilized a fixed, weight-based dosing protocol. The primary outcome was the percentage of patients in each group achieving a goal international normalization ratio of 1.4 or less. RESULTS: There was a significant difference in goal international normalization ratio achieved favoring Bebulin™ (85.5% vs 27.3%; P < .001) over Profilnine™. Median dose per kilogram of actual body weight was the same between the groups. When we assessed results by baseline™ international normalization ratio subgroup, more patients in the Bebulin™ group achieved goal when baseline values were 6 or less. No thrombotic events were documented in either group. CONCLUSIONS: We found that patients treated with Bebulin™ experienced significantly higher rates of successful international normalization ratio reversal when compared to those who received Profilnine™. Further research is needed to determine the comparative efficacy between the 2 agents.
Authors: Scott A Chapman; Eric D Irwin; Alan L Beal; Nichole M Kulinski; Katherine E Hutson; Melissa A L Thorson Journal: Ann Pharmacother Date: 2011-07-20 Impact factor: 3.154
Authors: Carolyn H Woo; Nihar Patel; Carol Conell; Vivek A Rao; Bonnie S Faigeles; Minal C Patel; Jasmeen Pombra; Paul T Akins; Yekaterina K Axelrod; Ivy Y Ge; William F Sheridan; Alexander C Flint Journal: World Neurosurg Date: 2012-12-05 Impact factor: 2.104
Authors: Farhan Siddiq; Abdul Jalil; Cara McDaniel; David G Brock; Carissa C Pineda; Rodney D Bell; Kiwon Lee Journal: Neurocrit Care Date: 2008 Impact factor: 3.210
Authors: Katherine P Cabral; Gilles L Fraser; Jennifer Duprey; Beth A Gibbons; Timothy Hayes; Jeffrey E Florman; David B Seder Journal: Clin Neurol Neurosurg Date: 2012-07-24 Impact factor: 1.876
Authors: Ryan Tilton; Elizabeth Landrum Michalets; Bethany Delk; Susan E Sutherland; Scott A Ramming Journal: Ann Pharmacother Date: 2014-06-04 Impact factor: 3.154
Authors: Jessica DeAngelo; Daniel Jarrell; Richard Cosgrove; James Camamo; Christopher Edwards; Asad E Patanwala Journal: Am J Ther Date: 2018 May/Jun Impact factor: 2.688